Millennium adding two cancer programs via Intellikine buy

Millennium: The Takeda Oncology Company will add two cancer drug candidates as part of Japanese parent Takeda Pharmaceutical Company Ltd.’s acquisition of Intellikine Inc.[1] of La Jolla, Calif., Takeda said today.

Millennium: The Takeda Oncology Company will add two cancer drug candidates as part of Japanese parent Takeda Pharmaceutical Company Ltd.'s acquisition of Intellikine Inc. of La Jolla, Calif., Takeda said today.